Lappe Mark

SEC Form 4 insider

Chief Executive Officer · Inhibrx Biosciences, Inc. ($INBX)

2 theses · first seen Sep 8, 2026

Window	Theses	Resolved	Wins	Win rate	Avg return	Median return
1d	2	2	1	50%	+2.4%	+2.4%
3d	2	2	1	50%	+0.5%	+0.5%
1w	2	2	1	50%	+3.8%	+3.8%
1m	1	1	0	0%	-18.9%	-18.9%
3m	0	0	0	—	—	—
6m	0	0	0	—	—	—
1y	0	0	0	—	—	—

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$INBXSEC Form 4bullish

Lappe Mark · Chief Executive Officer at Inhibrx Biosciences, Inc. · 19d ago1 prior · awaiting results

Long 10,040 shares of INBX

Bought 10,040 @ $84.56 avg · $848,977 · 2026-10-14

Form 4: Lappe Mark bought INBX

Lappe Mark (Chief Executive Officer at Inhibrx Biosciences, Inc.) reported an open-market purchase of 10,040 shares of INBX at an average $84.56, roughly $848,977, in a Form 4 filed 2026-10-14.

At post $85.26Now $72.16-15.4% since postedas of Nov 2, 4:15 PM ET

1d+6.1%

3d+5.4%

1w+15.2%

1m—

3m—

6m—

1y—

View filing on SEC.gov →

$INBXSEC Form 4bullish

Lappe Mark · Chief Executive Officer at Inhibrx Biosciences, Inc. · 55d ago1 prior · awaiting results

Long 25,000 shares of INBX

Bought 25,000 @ $105.82 avg · $2,645,399 · 2026-09-08

Form 4: Lappe Mark bought INBX

Lappe Mark (Chief Executive Officer at Inhibrx Biosciences, Inc.) reported an open-market purchase of 25,000 shares of INBX at an average $105.82, roughly $2,645,399, in a Form 4 filed 2026-09-08.

At post $114.34Now $72.16-36.9% since postedas of Nov 2, 4:15 PM ET

1d-1.3%

3d-4.4%

1w-7.6%

1m-18.9%

3m—

6m—

1y—

View filing on SEC.gov →

End of results.